Compare Ascendis Pharma A/S (ASND) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Berkshire Hathaway Inc Class B — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Berkshire Hathaway Inc Class B trades at $495.25. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| ASND | BRK.B | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Financials |
52-Week High | $277.18 | $513.70 |
52-Week Low | $163.32 | $459.10 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Berkshire Hathaway Class B shares (BRK.B) traded at $493.54, down 0.41% with a bearish technical signal. The stock shows mixed technical indicators with bullish moving averages but neutral oscillators. Analyst sentiment remains positive with 57% buy ratings and no sell recommendations. Support levels are established at $488-$492, while resistance sits at $497-$501.
The investment outlook remains favorable given strong analyst support and Berkshire's diversified business model. Key risks include market volatility and economic sensitivity, but the company's long-term track record provides stability. Earnings growth and portfolio performance will drive future price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
